1h Free Analyst Time
The epidermal growth factor receptor (EGFR) inhibitors market is forecasted to grow by USD 10.73 billion during 2024-2029, accelerating at a CAGR of 10.5% during the forecast period. The report on the epidermal growth factor receptor (EGFR) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in the prevalence of major cancer indications, increasing awareness and adoption of personalized medicine, and advancements in technology and research.
The epidermal growth factor receptor (EGFR) inhibitors market is segmented as below:
By Indication
- Lung cancer
- Colorectal cancer
- Breast cancer
- Others
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the epidermal growth factor receptor (EGFR) inhibitors market covers the following areas:
- Epidermal Growth Factor Receptor (EGFR) Inhibitors Market sizing
- Epidermal Growth Factor Receptor (EGFR) Inhibitors Market forecast
- Epidermal Growth Factor Receptor (EGFR) Inhibitors Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Indication
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global epidermal growth factor receptor (EGFR) inhibitors market: Amgen Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., Hutchison China Meditech Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Inc., Lutris Pharma, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Puma Biotechnology Inc., and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in research areas for treatment of various types of cancer."
According to the report, one of the major drivers for this market is the rise in the prevalence of major cancer indications.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- ASSERTIO HOLDINGS INC.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Checkpoint Therapeutics Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Hansoh Pharmaceutical Group Co. Ltd.
- Hutchison China Meditech Ltd.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Johnson and Johnson Inc.
- Lutris Pharma
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Puma Biotechnology Inc.
- Takeda Pharmaceutical Co. Ltd.
